341 related articles for article (PubMed ID: 16540726)
21. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma.
Choy B; Bandla S; Xia Y; Tan D; Pennathur A; Luketich JD; Godfrey TE; Peters JH; Sun J; Zhou Z
BMC Gastroenterol; 2012 Oct; 12():146. PubMed ID: 23078618
[TBL] [Abstract][Full Text] [Related]
22. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
[TBL] [Abstract][Full Text] [Related]
23. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
24. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
Hermann B; Li Y; Ray MB; Wo JM; Martin RC
Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
27. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.
Marketkar S; Li D; Yang D; Cao W
World J Gastroenterol; 2017 Feb; 23(8):1338-1344. PubMed ID: 28293080
[TBL] [Abstract][Full Text] [Related]
28. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
29. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
Soslow RA; Ying L; Altorki NK
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
[TBL] [Abstract][Full Text] [Related]
30. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
[TBL] [Abstract][Full Text] [Related]
31. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
32. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
33. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
[TBL] [Abstract][Full Text] [Related]
36. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
37. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
38. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
39. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Lu J; Lord RV
J Gastrointest Surg; 2010 Aug; 14(8):1207-13. PubMed ID: 20496011
[TBL] [Abstract][Full Text] [Related]
40. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus.
Bian YS; Osterheld MC; Bosman FT; Fontolliet C; Benhattar J
Am J Clin Pathol; 2000 Oct; 114(4):583-90. PubMed ID: 11026105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
